Pierrick Lefranc will succeed Aidan Murphy, Executive Vice President of Technical Operations and member of the Executive Committee, who will retire in March 2026 after 30 years at Ipsen. Since July 2019, Pierrick Lefranc has held the position of Senior Vice President at Ipsen, overseeing global production activities, engineering, and corporate excellence. He joined the group in 2013 and was appointed director of the Signes site in France in 2016. He will bring over 30 years of experience in the pharmaceutical industry. Pierrick Lefranc will be based in Paris and will report directly to David Loew, CEO.
Executive Endorsements
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
David Loew, CEO, expressed his pleasure in welcoming Pierrick Lefranc to the Executive Committee, highlighting his expertise in leadership and strategic transformation. He also thanked Aidan Murphy for his dedication and contribution to transforming Ipsen's technical operations. Pierrick Lefranc expressed his enthusiasm about joining the Executive Committee and his readiness to participate in the ongoing transformation of the group.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 190 millions d'euros
Quarterly revenue: 2 190 millions d'euros
Revenue growth: 20,4 %
EBITDA: 733,9 millions d'euros
EBITDA margin: 40,7 %
Net income: 403,1 millions d'euros
Free cash flow: 651,7 millions d'euros
-1 005 millions d'euros
Guidance from the release
Cette dynamique nous permet de relever nos objectifs financiers pour 2026
Risks mentioned
Arrivée potentielle de génériques du lanréotide, concurrençant les ventes de Somatuline
Effet défavorable des devises d'environ 1 % anticipé sur l'exercice 2026
Impact dilutif des acquisitions de Memo Therapeutics AG et de Kartos Therapeutics sur la marge
Opportunities identified
Plusieurs lancements attendus à court terme d'actifs à potentiel de blockbuster dans les trois aires thérapeutiques
Résultats positifs de Phase III de Dysport dans la migraine épisodique et chronique
Résultats positifs de Phase IIIb ELSPIRE d'Iqirvo dans la cholangite biliaire primitive
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
